Evidence for use of mood stabilizers and anticonvulsants in the treatment of nonaffective disorders in children and adolescents

Clinical Neuropharmacology

Volumn 33, Issue 6, 2010, Pages 303-311

  Amaladoss, Alfred ^a   Roberts, Nasreen ^a   Amaladoss, Franklin ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

anticonvulsants; childhood disruptive disorders; clinical review; mood stabilizers

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DESIPRAMINE; ETIRACETAM; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MOOD STABILIZER; OLANZAPINE; PHENYTOIN; PSYCHOSTIMULANT AGENT; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGGRESSION; AGITATION; ANOREXIA NERVOSA; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; BODY TEMPERATURE; BULIMIA; CHILD BEHAVIOR; CLINICAL TRIAL; COMORBIDITY; CONDUCT DISORDER; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; INTERMITTENT EXPLOSIVE DISORDER; LEUKOCYTE COUNT; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; NONAFFECTIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; POLYDIPSIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; STOMACH PAIN; THYROID DYSGENESIS; TREATMENT RESPONSE; TREMOR; TRICHOTILLOMANIA; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT BEHAVIOR; AFFECT; AGGRESSION; ANTICONVULSANTS; ANTIMANIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; HUMANS; IMPULSE CONTROL DISORDERS;

EID: 78649356762     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181f8d4ed     Document Type: Review

References (60)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Shaffer D, Fisher P, Davies M, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): Description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolescent Psychiatry 1996;35:865-877.
3. Rimm-Kaufman S, Pianta R, Cox M. Teachers judgement of problems in the transition to kindergarten. Early Child Res Q 2000;15:147-166.
4. Webster-Stratton C. Preventing conduct problems in Head Start Children: strengthening parent competencies. J Consult Clin Psychol 1998;66:715-730.
5. Webster-Stratton C, Reid M, Hammond M. Preventing conduct problems, promoting social competence: a parent and teaching partnership in Head Start. J Consult Clin Psychol 2001;30:283-302.
6. Blader J, Jensen P. Aggression in Children: an Integrative Approach, in Lewis' Textbook of Child and Adolescent Psychiatry. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2007.
7. Blader J, Schooler N, Jensen P, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry 2009;166:1392-1401.
8. Nagin D, Tremblay R. Parental and early childhood predictors of persistent physical aggression in boys from kindergarten to high school. Arch Gen Psychiatry 2001;58:389-394.
9. Rey J, Swayer M, Prior M. Similarities and differences between aggressive and delinquent children and adolescents in a national sample. Aust N J Psychiatry 2005;39:366-372.
10. Offord D, Boyle M, Szatmari P, et al. Ontario Child health study, II: six month prevalence of disorder and rates of service utilization. Arch Gen Psychiatry 1987;44:832-836.
11. Rutter M, Tizard J, Whitmore K. Education, Health, and Behavior. Melbourne, Australia: Krieger Publishing Co; 1970.
12. Stewart M, deBlois C, Meardon J, et al. Aggressive conduct disorder of children: the clinical picture. J Nerv Ment Dis 1980;168:604-610.
13. Lahey B, Loeber R, Burke J, et al. Predicting future antisocial personality disorder in males from a clinical assessment in childhood. J Consult Clin Psychol 2005;73:389-399.
14. Campbell M, Adans P, Small A, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995;5:445-453.
15. Rifkin A, Quitkin F, Klein D. Lithium in emotionally unstable character disorder. Arch Gen Psychiatry 1972;27:791-795.
16. Tupin J, Smith D, Clanon T, et al. Long term use of lithium in aggressive prisoners. Compr Psychiatry 1973;14:445-453.
17. Wilcox J. Divalproex sodium in the treatment of aggressive behavior. Ann Clin Psychiatry 1994;5:445-453.
18. Deluchhi GA, Calabrese J. Anticonvulsants for treatment of manic depression. Cleve Clin J Med 1989;56:756-761.
19. Harden C, Lazar L, Pick L, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999;40:1129-1134.
20. Ipser J, Stein D. Systematic review all pharmacotherapy of disruptive behavior disorders in children and adolescents. Psychopharmacology 2007;191:127-140.
21. Lopez-Larson M, Frazier J. Empirical evidence for the use of Lithium and anti-convulsants in children with psychiatric disorders. Harv Rev Psychiatry 2006;14:285-304.
22. Marcia P. Lithium: The First Mood Stabilizer. 2009. About.com Guide. Available at: http://bipolar.about.com/od/lithium/a/010312-lithium.htm
23. Adewuya E, Zinser W, Thomas C. Trichotillomania: a case of response to valproic acid. J Child Adolesc Psychopharmacol 2008;18:533-536.
24. Kastner T, Friedman D, Plummer A, et al. Valproic acid for the treatment of children with mental retardation and mood symptomatology. Pediatrics 1990;86:467-472.
25. Looker A, Conners CK. Diphenylhydantoin in children with severe temper tantrums. Arch Gen Psychiatry 1970;23:80-89.
26. Roach E, Delgado M, Anderson L, et al. Carbamazepine trial for Lesch-Nyan self mutilation. J Child Neurol 1996;11:476-478.
27. Khanzode L, Saxena K, Kraemer H, et al. Efficacy profiles of psychopharmacology: divalproex sodium in conduct disorder. Child Psychiatry Hum Dev 2006;37:55-64.
28. Steiner H, Petersen M, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 2003;64:1183-1191.
29. Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006;9:209-213.
30. Barzman D, McConville B, Materson B, et al. Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype. J Affect Disord 2005;88:279-285.
31. Donovan S, Susser E, Nunes E, et al. Divalproex treatment of disruptive adolescence: report of 10 cases. J Clin Psychiatry 1997;58:12-15.
32. Donovan S, Stewart J, Nunes E, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000;157: 818-820.
33. Campbell M, Small A, Green W, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984;41:650-656.
34. Malone R, Delaney M, Luebbert J, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000;57:649-654.
35. Masi G, Milone A, Manfredi A, et al. Effectiveness of lithium in children and adolescents with conduct disorder. CNS Drugs 2009;23:51-69.
36. Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorders in adolescents. Am J Psychiatry 1997;154:554-555.
37. Dickstein D, Towbin K, Van Der Veen J, et al. Randomized double-blind placebo-controlled trial of lithium in youths with severe dysregulation. J Child Adolesc Psychopharmacol 2009;19: 61-73.
38. Rugino T, Samsock T. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr 2002;23:225-230.
39. Wasserman S, Iyengar R, Chaplin W, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006;21:363-367.
40. Cueva J, Overall J, Small A, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996;35:480-490.
41. Dolengevich Segal H, Rodriguez Salgado B, Conejo Garcia A, et al. Efficacy of topiramate in children and adolescents with problems in impulse control: preliminary studies. Actas Esp Psiquiatr 2006;34:280-282.
42. Leibenluft E, Charney D, Towbin K, et al. Defining clinical phenotypes of juvenile mania. Am J Psychiatry 2003;160:430-437. (Pubitemid 41094250)
43. Pogge D, Wayland-Smith D, Zaccario M, et al. Diagnosis of manic episodes in adolescent in: structured diagnostic procedures compared to clinical chart diagnoses. Psychiatry Res 2001;101:47-54.
44. Reich W, Neuman R, Volk H, et al. Comorbidity between ADHD and symptoms of bipolar disorder in a community sample of children and adolescents. Twin Res Hum Genet 2005;8:459-466.
45. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. J Neuropsychopharmacol 2010;35:990-998.
46. Amiet C, Gourfinkel-An I, Bouzamondo A, et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. Biol Psychiatry 2008;64:577-582.
47. Malone R, Biesecker K, Delaney M, et al. Youth self report in aggression: baseline placebo responders and non-responders. Presented as a Conference Proceeding at the Scientific Proceedings of the Annual Meeting of the American Academyof Child & Adolescent Psychiatry. 1994 p. 49.
48. Martin A, Scahill L, Charney DS, Leckman JF, eds. Pediatric Psychopharmacology: Principles and Practice. New York, NY: Oxford University Press; 2003.
49. Swann A. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 2001;62:16-21.
50. Gallassi R, Morreale A, Lorusso S, et al. Cognitive effects of valproate. Epilepsy Res 1990;5:160-164.
51. Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins, a Wolters Kluwer Business; 2007.
52. Eland IA, Dofferhoff AS, Vink R, et al. Colitis may be part of the antiepileptic drug hypersensitivity syndrome. Epilepsia 1999;40: 1780-1783.
53. Lombardi SM, Girelli DG, Corrocher R. Severe multisystemic hypersensitivity reaction to carbamazepine including dyserythropoetic anemia. Ann Pharmacother 1999;33:571-575.
54. Kaufman KR. Carbamazepine, hepatoxicity, organic solvents and paints. Seizure 1999;8:250-252.
55. Morales-Diaz M, Pinilla-Roa E, Ruiz I. Suspected carbamazepine-induced hepatotoxicity. Pharmacotherapy 1999;19:252-255.
56. Bjoro K, Gjerstad L, Bentdal O, et al. Topiramate and fulminant liver failure [letter]. Lancet 1998;352:1119.
57. Konig SA, Siemes H, Baker F, et al. Severe hepato-toxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994;35:1005-1015.
58. Konig SA, Schenk M, Sick C, et al. Fatal liver failure associated with valproate therapy in a patient with Friedrich's disease: review of valproate hepatotoxicity in adults. Epilepsia 1999;40:1036-1040.
59. Preston JD, O'Neal JH, Talaga MC. Handbook of Clinical Psychopharmacology for Therapists. 3rd ed. Oakland, CA: New Harbinger Publication Inc; 2004.
60. Type II error definition. http://www.businessdictionary.com/definition/ type-2-error.html. Accessed 2010.